X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Proceeds drawn by LIDDS under the convertible notes agreement will be used to further advance the project in clinical development, creating a solid foundation for new partnerships and license agreements for Liproca, based on the NanoZolid® technology.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Liproca
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nice & Green
Deal Size: $4.3 million Upfront Cash: Undisclosed
Deal Type: Financing February 22, 2022
Details:
NZ-DTX-001 is intratumoural depot formulation of NanoZolid® in combination with docetaxel for treatment of solid tumors.
Lead Product(s): NanoZolid-Docetaxel
Therapeutic Area: Oncology Product Name: NZ-DTX
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: NZ-DTX
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot.
Lead Product(s): NZ-TLR9
Therapeutic Area: Oncology Product Name: NZ-TLR9
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Pharmidea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2021
Details:
The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Liproca Depot
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
The results indicate that NanoZolid technology®, with controlled & sustained drug release, can be used to treat deep lying cancer tumors, which are not suitable to be treated with standard TLR9 due to the necessity of weekly injections.
Lead Product(s): NZ-TLR9
Therapeutic Area: Oncology Product Name: NZ-TLR9
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
In patients who received a second Liproca® Depot injection (6 of 12), at 2 months post treatment, PSA levels were in average reduced by 28 %.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Liproca Depot
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Final data from the LPC-004 study confirms Liproca® Depot’s potential as a safe and effective anti-androgen treatment for prostate cancer patients that currently are not treated but kept under ‘Active Surveillance’.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
Dose escalation in the Phase I study NZ-DTX is proceeding according to the protocol, with additional patients being treated at a higher dose level of NZ-DTX.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
Clinical data have shown that intratumoral delivery of TLR9 agonists can effectively treat solid cancers.
Lead Product(s): NZ-TLR9
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
